We will not forget ENDO 2022 any time soon. Nothing compared to the elation of seeing long-time friends face-to-face after spending nearly two years connected only through computer screens! We will continue to focus on knowledge exchange and networking at ENDO 2023, which will take place in Chicago from June 15 to 18, 2023. Based...
During ENDO 2022, the Endocrine Society made a community-wide “house call” with a flagship EndoCares® event that brought care and compassion to an underserved population. On Saturday June 11, the atmosphere at the Clarkston Community Center in Clarkston, Ga., could only be described as festive. The red brick building was filled with neighbors visiting...
A study presented at ENDO 2022 laid bare the excess direct healthcare costs of mental health disorders associated with polycystic ovary syndrome (PCOS) in the United States, finding those costs reached almost $6 billion in 2021. The authors of the study point out that PCOS affects one in seven reproductive-aged women worldwide, and represents a...
Amidst of the throngs of ENDO 2022 attendees, Olympian Gail Devers took centerstage to discuss living with and overcoming Graves’ disease and thyroid eye disease. She teamed up with endocrinologist Eve D. Bloomgarden, MD, to tout the importance of patient/physician teamwork and why patients need to champion their own healthcare. In a lot of ways,...
A study presented at ENDO 2022 in Atlanta this past summer suggests that active testosterone therapy for transgender men may negatively impact IVF outcomes. Research presented by Amanda Schwartz, MD, a reproductive endocrinology and infertility fellow at the University of Michigan, found that female mice currently receiving testosterone had fewer and less developed eggs retrieved....
Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a study presented at ENDO 2022. The authors of the study point out that a well-established relationship between diabetes and breast cancer exists, but it’s still unclear how...
ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...
Meta-analysis presented at ENDO 2022 provides real-world evidence that a test can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules and that, when the test deems a nodule as suspicious, the patient’s risk of malignancy is consistent, and higher than that reported in the test’s original clinical validation (CV) study. Veracyte is...
We will not forget ENDO 2022 any time soon. Nothing compared to the elation of seeing long-time friends face-to-face after spending nearly two years connected only through computer screens! We will continue to focus on knowledge exchange and networking at ENDO 2023, which will take place in Chicago from June 15 to 18, 2023. Based...
During ENDO 2022, the Endocrine Society made a community-wide “house call” with a flagship EndoCares® event that brought care and compassion to an underserved population. On Saturday June 11, the atmosphere at the Clarkston Community Center in Clarkston, Ga., could only be described as festive. The red brick building was filled with neighbors visiting...
Amidst of the throngs of ENDO 2022 attendees, Olympian Gail Devers took centerstage to discuss living with and overcoming Graves’ disease and thyroid eye disease. She teamed up with endocrinologist Eve D. Bloomgarden, MD, to tout the importance of patient/physician teamwork and why patients need to champion their own healthcare. In a lot of ways,...
